
The new BiTE antibody technology developed by the company can simultaneously engage 2 different targets, which can help recruit T-cells to malignant cells, and will be evaluated in ALL patients.

The new BiTE antibody technology developed by the company can simultaneously engage 2 different targets, which can help recruit T-cells to malignant cells, and will be evaluated in ALL patients.

The approval follows 2 clinical trials evaluating the regimen in 1720 cancer patients receiving chemotherapy.

The approval extends the use of bortezomib beyond relapsed and refractory patients.

The identification of specific RNA molecules in the urine of individuals with prostate cancer raises hope for a non-invasive test for the disease.

Having decided to restrict the distribution of 3 of its top-selling oncology medications, Avastin, Rituxan, and Herceptin only through specialty pharmacies, Genentech is witnessing protests in various forms from healthcare centers.


















The collaboration between med fusion and GenomOncology promises improved outcomes in personalized cancer trials.

A Taiwan study found a significantly reduced risk of cancer among RA patients on biologics.

Results of a large study performed across cancer centers in Germany, published online October 6, 2014 in the Journal of Clinical Oncology, show that 32% of people with cancer experienced some form of clinically relevant mental health challenge, such as anxiety, depressive and adjustment disorders.

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
